JPMorgan Chase & Co. Has $416,000 Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM)

JPMorgan Chase & Co. boosted its holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) by 1,040.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 28,426 shares of the company’s stock after purchasing an additional 25,934 shares during the quarter. JPMorgan Chase & Co. owned 0.11% of Contineum Therapeutics worth $416,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Corebridge Financial Inc. raised its position in shares of Contineum Therapeutics by 73.1% in the fourth quarter. Corebridge Financial Inc. now owns 5,215 shares of the company’s stock valued at $76,000 after buying an additional 2,202 shares in the last quarter. Rhumbline Advisers increased its stake in Contineum Therapeutics by 36.3% during the 4th quarter. Rhumbline Advisers now owns 8,233 shares of the company’s stock worth $121,000 after acquiring an additional 2,191 shares during the period. Barclays PLC raised its holdings in Contineum Therapeutics by 248.6% in the 3rd quarter. Barclays PLC now owns 8,308 shares of the company’s stock valued at $158,000 after acquiring an additional 5,925 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Contineum Therapeutics by 32.3% during the 4th quarter. Bank of New York Mellon Corp now owns 18,738 shares of the company’s stock valued at $275,000 after acquiring an additional 4,573 shares during the period. Finally, WINTON GROUP Ltd grew its holdings in shares of Contineum Therapeutics by 256.8% during the 4th quarter. WINTON GROUP Ltd now owns 39,738 shares of the company’s stock worth $582,000 after purchasing an additional 28,602 shares in the last quarter.

Contineum Therapeutics Trading Down 3.4 %

CTNM opened at $3.97 on Friday. The company has a market cap of $102.71 million and a P/E ratio of -0.81. The company’s 50 day moving average is $5.96 and its 200-day moving average is $10.93. Contineum Therapeutics, Inc. has a 1-year low of $3.69 and a 1-year high of $22.00.

Analysts Set New Price Targets

CTNM has been the subject of a number of analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $31.00 price target on shares of Contineum Therapeutics in a research note on Thursday, January 9th. Jones Trading began coverage on shares of Contineum Therapeutics in a research report on Thursday, March 13th. They issued a “buy” rating and a $23.00 target price for the company. Robert W. Baird reduced their price target on shares of Contineum Therapeutics from $32.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, March 7th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $25.00 price objective on shares of Contineum Therapeutics in a research note on Friday, March 7th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $23.75.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).